Abstract
Cisplatin [cis-diamminedichloroplatinum(II)] is a widely used antitumor drug with dose-limiting nephrotoxic side effects due to selective toxicity to the proximal tubule. In the present study, the chemoprotective potential of three selenocysteineSe-conjugates,Se-methyl-l-selenocysteine,Se-(2-methoxyphenyl)-l-selenocysteine, andSe-(2-chlorobenzyl)-l-selenocysteine, belonging to three structural classes, against the nephrotoxic effects of cisplatin was investigated. SelenocysteineSe-conjugates have previously been proposed as kidney-selective prodrugs of pharmacologically active selenols because of their active uptake and bioactivation by cysteine conjugate β-lyases in the kidney. To elucidate whether chemoprotection is β-lyase-dependent wild-type LLC-PK1 cells, possessing a very low β-lyase activity, and LLC-PK1 cells stably transfected with full-length cDNA coding for rat kidney cysteine conjugate β-lyase/glutamine transaminase K (R1J) were used. The results indicate that all three selenocysteineSe-conjugates were able to attenuate the cisplatin-induced loss of viability in R1J cells but not in the parental LLC-PK1 cells, as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and neutral red uptake. In addition, cisplatin-induced reactive oxygen species (ROS) production was determined using 2′,7′-dichlorodihydrofluorescein diacetate. The selenocysteineSe-conjugates were able to decrease ROS levels after cisplatin exposure in both cell types. However, this ROS-protective effect was more profound in R1J cells.Se-Methyl-l-selenocysteine provided the strongest protection. The protective activity against cisplatin-induced cytotoxicity and ROS generation was blocked by aminooxyacetic acid, a selective inhibitor of pyridoxal 5′-phosphate-dependent cysteine conjugate β-lyases, further supporting the role of β-lyase in the observed chemoprotection. The precise molecular mechanism by which selenols, generated by β-lyase, provide protection against cisplatin-induced cytotoxicity, however, remains to be established.
Footnotes
-
↵1 M.R. and G.S. contributed equally to this study.
-
This work was supported by Grant C95.1535 from the Dutch Kidney Foundation.
- Abbreviations:
- SeCys
- selenocysteine Se
- PLP
- pyridoxal 5′-phosphate
- β-lyase/GTK
- cysteine conjugate β-lyase/glutamine transaminase K
- ROS
- reactive oxygen species
- PTC
- proximal tubular cell
- AOAA
- aminooxyacetic acid
- MTT
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- MSeCys
- Se-methyl-l-selenocysteine
- H2DCF-DA
- 2′,7′-dichlorodihydrofluorescein diacetate
- MPSeCys
- Se-(2-methoxyphenyl)-l-selenocysteine
- CBSeCys
- Se-(2-chlorobenzyl)-l-selenocysteine
- TFE-Cys
- S-(1,1,2,2-tetrafluoroethyl)-l-cysteine
- DMEM
- Dulbecco's modified Eagle's medium
- FCS
- fetal calf serum
- PBS
- phosphate-buffered saline
- ANOVA
- analysis of variance
- Received October 10, 2001.
- Accepted January 28, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|